Conversely to IL-2, decreased levels of IL-6 by asciminib and the other TKIs might be beneficial for the course of CML since IL-6-levels in the serum of CML patients were increased and it was additionally shown in a mouse model that IL-6 directly contributes to the development of CML [33, 34]. The gene discussed is IL2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.